Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab

BACKGROUND: BCD-022 is a trastuzumab biosimilar which was shown to be equivalent to reference trastuzumab in a wide panel of physicochemical studies as well as preclinical studies in vitro and in vivo. International multicenter phase III clinical trial was conducted to comparatively assess efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexeev, Sergey M., Khorinko, Andrey V., Mukhametshina, Guzel Z., Shelepen, Konstantin G., Burdaeva, Olga N., Kulik, Sergey A., Satheesh, Chiradoni Thugappa, Srivastava, Kirti, Vikranth, Mummaneni, Kryukov, Fedor, Paltusova, Anastasia N., Shustova, Mariya S., Ivanov, Roman A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439710/
https://www.ncbi.nlm.nih.gov/pubmed/32819305
http://dx.doi.org/10.1186/s12885-020-07247-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439710/
https://www.ncbi.nlm.nih.gov/pubmed/32819305
http://dx.doi.org/10.1186/s12885-020-07247-9

Ejemplares similares